Contraception Clinical Trial
— PPIUDOfficial title:
A Pilot Study Of A Randomized Trial Comparing Two Different Time Frames For Copper T380A Intrauterine Contraception Insertion; Immediately Postpartum Compared To 4-6 Weeks Postpartum In Lilongwe, Malawi
The purpose of this non-blinded randomized clinical trial is to pilot the design of a
randomized clinical trial to be conducted in Malawi to investigate immediate postpartum
insertion of the Copper T380 intrauterine contraceptive device (CuT380A-IUCD) compared to
placement at the 6-week postpartum visit.
The investigators hypothesize that it will be feasible to enroll 140 women into this study,
and that women will find the 10 minute to 48 hour time frame for IUCD placement acceptable.
Status | Completed |
Enrollment | 115 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Primary Inclusion Criteria: - Ages 18-45 attending prenatal care - Greater than 34 weeks estimated gestational age - Desire to use the CuT380A-IUCD for contraception postpartum - Plan to stay in the area for at least 5 months postpartum - If HIV+ the women must be WHO Clinical Stage 1 or 2, or known to be clinically well on antiretroviral therapy as documented in their health passport - No prior cesarean delivery - No treatment for pelvic inflammatory disease within 3 months prior to pregnancy - No known uterine anomalies - No known pelvic tuberculosis - No known genital tract cancer - No known allergy to copper - No known history of ectopic pregnancy within 3 months prior to pregnancy. - No evidence of clinical anemia as assessed by a clinician at enrollment - Any other condition a clinician feels should preclude the woman from receiving the IUCD 10-minutes to 48 hours after delivery Secondary Eligibility Criteria - Vaginal delivery within the last 48 hours - No postpartum hemorrhage documented by the delivering clinician - Not known to have ruptured membranes for greater than 24 hours prior to delivery - No infection diagnosed by a clinician - No fever of greater than 38° during labour or delivery - Any other condition which a clinician feels precludes the woman from receiving the IUCD 10 minutes to 48 hours after delivery. Exclusion Criteria: - prior cesarean section - fever during labor and delivery - AIDS, not well on antiretroviral therapy - genital tuberculosis - known uterine abnormalities or genital tract cancer - history of ectopic pregnancy within 3 months of current pregnancy |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
Malawi | University of North Carolina Project Lilongwe | Lilongwe |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill |
Malawi,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time | Estimate the time required to enroll 140 women into this study | 6 months | No |
Secondary | Expulsion rates | Estimate the expulsion rate of the CuT380A-IUCD | 6 months | No |
Secondary | Satisfaction | Assess patient and provider satisfaction when the CuT380A-IUCD is placed 10 minutes - 48-hours postpartum. | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |